Simurosertib

Simurosertib is an inhibitor of cell division cycle 7 (Cdc7) kinase (IC₅₀ = 0.26 nM).¹ It is selective for Cdc7 over cyclin-dependent kinase 2 (Cdk2) and Rho-associated kinase 1 (ROCK1; IC₅₀s = 6,300 and 430 nM, respectively). It inhibits phosphorylation of DNA replication licensing factor MCM2 in HeLa cells (IC50 = 17 nM) and reduces proliferation of COLO 205 cells (EC₅₀ = 81 nM). Simurosertib induces replication stress, halts the cell cycle at the G₂/S phase, and inhibits the growth of a wide variety of cancer cells (GI₅₀s = 30.2->10,000 nM).² It reduces intratumor levels of phosphorylated MCM2 in COLO 205 and SW948 mouse xenograft models when administered at a dose of 80 mg/kg and reduces tumor growth in the same models when administered at doses of 40 or 60 mg/kg twice per day.

WARNING This product is not for human or veterinary use.

1. Kurasawa, O., Miyazaki, T., Homma, M., et al. Discovery of a novel, highly potent, and selective thieno[3,2- d]pyrimidinone-based cdc7 inhibitor with a quinuclidine moiety (tak-931) as an orally active investigational antitumor agent. J. Med. Chem. 63(3), 1084-1104 (2020).

2. Iwai, K., Nambu, T., Dairiki, R., et al. Molecular mechanism and potential target indication of TAK-931, a novel CDC7-selective inhibitor. Sci. Adv. 5(5), eaav3660 (2019).